Governor Martin O'Malley (left) greets philanthropist Stewart Greenebaum during the January 17 NCI site visit to UMGCC.
On January 17, 2008, the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) hosted a team of reviewers from the National Cancer Institute to evaluate our application for NCI cancer center designation.
The day-long site visit was the culmination of a comprehensive, multi-year study process that involved carefully detailing the structure and programs of the cancer center, the progress we have made in basic and clinical research, and our effectiveness in the providing outstanding care to cancer patients in our city, our State and increasingly from around the world.
See article in The Daily Record about the NCI designation process.
According to the National Cancer Institute Web site, NCI-designated cancer centers are ". . . characterized by scientific excellence and the capability to integrate a diversity of research approaches to focus on the problem of cancer. They play a vital role in advancing towards our goal of reducing morbidity and mortality from cancer.” Research performed at UMGCC has received significant national and international recognition, particularly honoring the pioneering work of Dr. Angela Brodie for the development of aromatase inhibitors, now the standard treatment for breast cancer worldwide.
Governor Martin O’Malley was on hand to greet the NCI site visit team and report on the cancer center’s important contributions to the health and well-being of the citizens of Maryland. Cancer center benefactors Marlene and Stewart Greenebaum were also in attendance during the site visit presentations by program leaders.
In a message to all cancer center staff in advance of the site visit, Dr. Kevin Cullen, cancer center director, said: “Our center has truly emerged on a national and international level thanks to your collective efforts and the wonderful support we have received from many sources. I thank all of you for making this moment possible. Whatever the outcome of tomorrow's visit, we should be very proud of what we have grown and look forward with great optimism for the future.”
UMGCC’s application for NCI designation will be scored on the basis of clinical and translational research programs, faculty recruitment, shared service development, clinical and laboratory infrastructure, as well as construction and renovation of cancer research and clinical facilities. Official notification of the outcome of the application for NCI cancer center designation is due in early 2009.
For more information about the programs and services of the University of Maryland Marlene and Stewart Greenebaum Cancer Center, please call 1-800-888-8823.